# Chimeric Antigen Receptor T Cells Targeting Glypican-3

> **NCT03884751** · PHASE1 · COMPLETED · sponsor: **CARsgen Therapeutics Co., Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** CAR-GPC3 T Cells

## Key facts

- **NCT ID:** NCT03884751
- **Lead sponsor:** CARsgen Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-15
- **Primary completion:** 2021-05-28
- **Final completion:** 2021-12-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2022-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03884751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03884751, "Chimeric Antigen Receptor T Cells Targeting Glypican-3". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03884751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*